Clinical trials: Hemostatic Disorders
Leukemia, Lymphoma
Study of Hypotensive Hematopoietic Malignancy Patients' USCOM Readings
The purpose of this study is to test how practical it is to use the Ultrasonic Cardiac Output Monitor (USCOM), an FDA-approved device, on oncology patients (specifically those with blood cancers).
- Conditions
- Leukemia, Lymphoma, Paraproteinemias, Multiple Myeloma
- Trial name
- NCT01755000
- Testing
- USCOM scan, Fluid Bolus
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Washington University School of Medicine
DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma
Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma
This phase II trial studies lenalidomide, dexamethasone, and clarithromycin in treating patients who have undergone stem cell transplant for multiple myeloma.
- Conditions
- DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NCT00445692
- Testing
- Clarithromycin, Dexamethasone, Lenalidomide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma
A Registry Study of Participants With Multiple Myeloma in Latin America
The purpose of this study is to characterize the multiple myeloma (MM) population concerning demographics and clinical characteristics (for example.
- Trial name
- MYLACRE (NCT03955900)
- Testing
- No intervention
- Where
- 22 sites in Argentina, Brazil and 3 more
- Volunteers
- 2,059 people
- Sponsor
- Janssen-Cilag Ltd.
Multiple Myeloma, Lymphoma, Non-Hodgkin
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Background: Cancer has a major impact in the United States and across the world. In 2015, over 1.5 million new cases of cancer were diagnosed in the U.S.
- Conditions
- Multiple Myeloma, Lymphoma, Non-Hodgkin, Leukemia-Lymphoma, Adult T-Cell, Hodgkin Disease
- Trial name
- NCT02682667
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma and Plasma Cell Neoplasm
Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill…
- Trial name
- NCT00003007
- Testing
- recombinant interferon alfa, sargramostim, cyclophosphamide
- Where
- 4 sites in United States
- Sponsor
- University of Tennessee
Pseudoxanthoma Elasticum
Oral Pyrophosphate Absorption in PXE Disease
Pyrophosphate is an endogenous, non-toxic metabolite inhibiting soft tissue calcification. The aim of our study is to find optimal dosing and safety of oral disodium-PPi (Na2H2PPi).
- Trial name
- NCT04441671
- Testing
- Disodium Pyrophosphate
- Sponsor
- Tampere University Hospital
Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
This phase II trial studies how well nivolumab works for the treatment of hematological malignancies that have come back (relapsed), does not respond (refractory), or is detectable after CAR T cell therapy.
- Conditions
- Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma
- Trial name
- NCT04205409
- Testing
- Nivolumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Washington
Myeloma Multiple
Immune Fitness in Older Patients With Relapsed and Refractory Multiple Myeloma
Relapsed/refractory multiple myeloma (RRMM) predominantly affects older adults, who exhibit marked heterogeneity in treatment outcomes despite receiving the same therapies.
- Trial name
- PRIME (NCT07674498)
- Testing
- immunophenotyping of lymphocyte
- Where
- 3 sites in Belgium
- Volunteers
- 31 people
- Sponsor
- Jules Bordet Institute
Hemorrhagic Hereditary Telangiectasia (HHT)
Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hemorrhagic Hereditary Telangiectasia (HHT)
The recognized manifestations of HHT are all due to abnormalities in vascular structure. Epistaxis due to telangiectases formation is spontaneous, very variable, recurrent in 90% of patients, and associated with severe anemia in…
- Trial name
- TACRO (NCT03152019)
- Testing
- Protopic® (Tacrolimus) 0.1% ointment
- Where
- 3 sites in France
- Volunteers
- 50 people
- Sponsor
- Hospices Civils de Lyon
Blood Loss, Surgical
Pre-surgical Evaluation for the Quantra System in Adult Patients Undergoing Cardiac Surgery
This study will evaluate the performance of the Quantra System comprised of the Quantra Hemostasis Analyzer with the QPlus Cartridge in patients taking anitplatelet medication that are scheduled to undergo cardiac surgery.
- Trial name
- NCT03931031
- Testing
- Quantra System
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- HemoSonics LLC
Primary Haemostasis Disorder in Cardiac Surgery Patients
Relation Between the Value of Platelet Clot Stiffness (PCS) Obtained by Sonorheometric Method of Delocalized Hemostasis (QUANTRA®), and the Presence of a Disorder of Primary Hemostasis, in Cardiac Surgery Patients. PLAQUA-Study
The goal of this study is to determine whether the Platelet Clot Stiffness (PCS) measured by QUANTRA® is predictive of an abnormality in primary haemostasis intraoperatively in cardiac surgery performed under extracorporeal…
- Trial name
- PLAQUA (NCT06585930)
- Testing
- Blood sample
- Where
- Reunion
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Hematopoietic Cell Transplantation Recipient, Recurrent Plasma Cell Myeloma
Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant
This randomized phase II trial studies the side effects and how well melphalan hydrochloride works in treating patients with multiple myeloma that has come back or does not respond to treatment.
- Conditions
- Hematopoietic Cell Transplantation Recipient, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NCT03328936
- Testing
- Laboratory Biomarker Analysis, Melphalan Hydrochloride, Pharmacological Study
- Where
- United States
- Sponsor
- Ohio State University Comprehensive Cancer Center
Coagulation Defects
Safety Study of Spray-Dried Solvent/Detergent-Treated Plasma for Infusion in Healthy Volunteers
This study is a Phase 1, single-center, open-label, ascending dose study which will assess the safety and tolerability of 5 doses of spray-dried solvent/detergent treated plasma (Resusix®) in healthy volunteers.
- Trial name
- NCT01589666
- Testing
- Spray-dried S/D-treated Plasma
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Entegrion, Inc.
Multiple Myeloma, Multiple Myeloma in Relapse
Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies
This phase II trial tests whether pembrolizumab works to shrink tumors in patients with multiple myeloma whose cancer has come back (relapsed) or did not respond to previous treatment (refractory) with anti-BCMA CAR-T therapies.
- Conditions
- Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Recurrent Plasma Cell Myeloma
- Trial name
- NCT05191472
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Alfred Chung, MD
Multiple Myeloma
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
This study evaluates an individualized approach combining highly active maintenance treatment with elranatamab with peripheral blood-based clonotypic measurable residual disease (MRD) testing in patients with newly diagnosed…
- Trial name
- NCT06483100
- Testing
- Elrantamab, clonoSEQ
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Washington University School of Medicine
Relapsed or Refractory Multiple Myeloma
Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma
This study evaluates the safety and efficacy of novel BCMA-targeted CAR-T cell therapy (CBG-002) for patients with relapsed or refractory multiple myeloma (r/r MM).
- Trial name
- NCT04706936
- Testing
- anti-BCMA CAR-T, Cyclophosphamid, Fludarabine
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Multiple Myeloma
Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy
This is a randomized, 2-arm phase II, multi-center study to evaluate the overall response rate in newly diagnosed, transplant ineligible patients receiving 9 cycles induction therapy with either KTd or KRd followed by…
- Trial name
- NCT02891811
- Testing
- Carfilzomib, Thalidomide, Lenalidomide
- Where
- 21 sites in Austria, Germany
- Volunteers
- 124 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Hemorrhoids, Bleeding Disorder
Sclerotherapy With Polidocanol Foam In The Treatment Of Hemorrhoidal Disease In Patients With Bleeding Disorders
Treatment of hemorrhoidal disease includes a conservative approach (dietary and behavioral measures, venotropic and topical medication), office-based treatments and surgery.
- Trial name
- NCT04188171
- Testing
- Polidocanol foam sclerotherapy
- Where
- 3 sites in Portugal
- Volunteers
- 150 people
- Sponsor
- Universidade do Porto
Multiple Myeloma
Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma
Multiple myeloma cells are dependent on calcium (Ca2+) for their function. Specifically, Ca2+ is required for the function of the endoplasmic reticulum in which proteins, including immunoglobulins, are folded prior to their…
- Trial name
- NCT01965834
- Testing
- Fenofibrate
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Miami
Leukemia, Lymphoma
Early Integration of Palliative and Supportive Care in Cellular Therapy
Research has shown that early palliative care in cancer care is associated with improved symptom management, better prognostic understanding, improved quality of life for patients and family caregivers, and even improved…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Blood Cancer
- Trial name
- PALS_CT (NCT05190653)
- Testing
- Early palliative and supportive care
- Where
- Canada
- Volunteers
- 152 people
- Sponsor
- Alberta Health Services, Calgary
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.